Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.32 |
| ▸ | PPARG | P37231 | 3/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.32 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.32 |
| ▸ | F10 | P00742 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL6165992 | 1.00 | KLKB1 (0.33) | KLKB1MAPTPDE3BPDE3AEPHX2 | |
| Trifluoroacetic Acid SCHEMBL6165673 | 0.93 | EPHX2 (0.40) | KLKB1MAPTEPHX2PPARGF10 | |
| Trifluoroacetic Acid SCHEMBL6165679 | 0.93 | EPHX2 (0.40) | KLKB1MAPTEPHX2PPARGF10 | |
| Trifluoroacetic Acid SCHEMBL6167880 | 0.93 | SMN1; SMN2 (0.34) | MAPTPDE3BPDE3AKMT2ASMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL6167885 | 0.93 | SMN1; SMN2 (0.34) | MAPTPDE3BPDE3AKMT2ASMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL6173089 | 0.93 | MAPT (0.39) | MAPTKMT2ASMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL6173094 | 0.93 | MAPT (0.39) | MAPTKMT2ASMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL7106592 | 0.92 | GRM2 (0.34) | MAPTPDE3BPDE3AKMT2ASMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL7106589 | 0.92 | GRM2 (0.34) | MAPTPDE3BPDE3AKMT2ASMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL6161851 | 0.92 | PDE3B (0.38) | MAPTPDE3BPDE3AKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030065176-A1 | Factor xa inhibitors with aryl-amidines and derivatives, and prodrugs thereof | LG CHEM INVESTMENT LTD. (KR) | 2003-04-03 | — | — | US | claimed |
| EP-1254136-A4 | FACTOR Xa INHIBITORS WITH ARYL-AMIDINES AND DERIVATIVES, AND PRODRUGS THEREOF | LG CHEM INVESTMENT LTD (KR) | 2005-06-01 | — | — | EP | disclosed |
| US-20030065176-A1 | Factor xa inhibitors with aryl-amidines and derivatives, and prodrugs thereof | LG CHEM INVESTMENT LTD. (KR) | 2003-04-03 | — | — | US | disclosed |
| EP-1254136-A1 | FACTOR Xa INHIBITORS WITH ARYL-AMIDINES AND DERIVATIVES, AND PRODRUGS THEREOF | LG Chem Investment, Ltd. (KR) | 2002-11-06 | — | — | EP | disclosed |
| WO-2001055146-A1 | FACTOR Xa INHIBITORS WITH ARYL-AMIDINES AND DERIVATIVES, AND PRODRUGS THEREOF | LG CHEM INVESTMENT LTD. (KR) | 2001-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065176-A1 | Factor xa inhibitors with aryl-amidines and derivatives, and prodrugs thereof | F2, F12, TFPI | KLKB1 530/4885MAPT 4356/4885PDE3B 211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.